Calcium gluconate is a blood coagulation factor indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. It is available as injection for intravenous use. MedsAcross supplies Calcium gluconate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Calcium Gluconate Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established.
Source: US FDA prescribing information
Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are normal constituents of body fluids.
Source: US FDA prescribing information
Contains 100 mg of calcium gluconate per mL which contains 9.3 mg (0.465 mEq) of elemental calcium. Administer intravenously (bolus or continuous infusion) via a secure intravenous line. See Full Prescribing Information (FPI) for dilution instructions, administration rates, and appropriate monitoring. Individualize the dose within the recommended range in adults and pediatric patients depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia. See Table 1 in the FPI for dosing recommendations in mg of calcium gluconate for neonates, pediatric and adult patients. Measure serum calcium during intermittent infusions every 4 to 6 hours and during continuous infusion every 1 to 4 hours. Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed.
Source: US FDA prescribing information
Calcium Gluconate Injection is contraindicated in: Hypercalcemia Neonates (28 days of age or younger) receiving ceftriaxone Hypercalcemia. Neonates (28 days of age or younger) receiving ceftriaxone
Source: US FDA prescribing information
Arrhythmias with Concomitant Cardiac Glycoside Use: If concomitant therapy is necessary, Calcium Gluconate Injection should be given slowly in small amounts and close ECG monitoring is recommended. End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates: Concurrent use of intravenous ceftriaxone may cause life-threatening precipitates. Cases of fatal outcomes in neonates have occurred. Tissue Necrosis and Calcinosis: Calcinosis cutis can occur with or without extravasation of Calcium Gluconate Injection. Tissue necrosis, ulceration, and secondary infection are the most serious complications. If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed.
Source: US FDA prescribing information
The following serious adverse reactions are also described elsewhere in the labeling: Arrhythmias with Concomitant Cardiac Glycoside Use End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates Tissue Necrosis and Calcinosis Hypotension, Bradycardia, and Cardiac Arrhythmias Aluminum toxicity The following adverse reactions associated with the use of calcium gluconate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Source: US FDA prescribing information
Cardiac Glycoside: Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. Calcium Channel Blockers: Administration of calcium may reduce the response. Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F). Do not freeze. The precipitate, if present, may be dissolved by warming the vial to 60° to 80°C, with occasional agitation, until the solution becomes clear. Allow to cool to room temperature before dispensing.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Calcium gluconate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Calcium gluconate 980 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 4900 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 9800 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 1000 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 10000 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 2000 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 1000 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 5000 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Calcium gluconate 1000 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 15 June 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Calcium gluconate in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 9 presentations of Calcium gluconate and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Calcium gluconate on 15 June 2017, according to Drugs@FDA.
No listed presentation of Calcium gluconate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Calcium gluconate is classified under ATC code A12AA03 (Calcium gluconate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.